Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% ...
Penumbra could generate healthy sales and earnings growth, gaining market share in MT. MT’s share would rise to around 50% in DVT and about 60% in PE. Don’t miss this list of 3 high-yield ...
Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, ...
Penumbra's stock has sold off sharply over the last year as decelerating revenue growth has spooked growth investors out of this high-multiple stock. Q2 results included 14% revenue growth, a small ...
"This is an important milestone that underscores Penumbra's commitment to transforming care for patients with pulmonary embolism," said James F. Benenati, MD, FSIR, chief medical officer at Penumbra. ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min At Penumbra Inc. Shruthi Narayan ...
Zacks.com on MSN
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Penumbra, Inc.’s PEN robust product portfolio expansion is poised to drive growth in the upcoming quarters. Additionally, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback